Tenshi Pharmaceuticals Private Limited has Submitted to the Exchange a copy of Disclosure under Regulation 31(4) of the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.
ONESOURCE · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Onesource Specialty Pharma's promoters and promoter group (acting through Tenshi Pharmaceuticals Private Limited) have filed a declaration with the stock exchanges confirming they did not create any new encumbrance (pledge, lien, or charge) on their shareholding in the company during the financial year ended 31 March 2025. The disclosure is a routine annual compliance requirement under SEBI's takeover regulations. The filing was signed by Shridhara Kela, Director of Tenshi Pharmaceuticals. No financial figures or new transactions are disclosed.
This is a routine compliance filing with no material impact on the stock. It is mildly reassuring as it confirms promoters have not pledged additional shares during the year, though it does not guarantee their shares are unencumbered overall.